Get the Stockscreener App
5.325
2.01%
0.105
Protara Therapeutics Inc stock is traded at $5.325, with a volume of 261.12K.
It is up +2.01% in the last 24 hours and up +69.59% over the past month.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
See More
Previous Close:
$5.22
Open:
$5.32
24h Volume:
261.12K
Relative Volume:
0.72
Market Cap:
$206.03M
Revenue:
-
Net Income/Loss:
$-42.05M
P/E Ratio:
-1.8883
EPS:
-2.82
Net Cash Flow:
$-35.26M
1W Performance:
+9.34%
1M Performance:
+69.59%
6M Performance:
+36.19%
1Y Performance:
+216.96%
1-Day Range:
$5.2301
$5.43
1-Week Range:
$4.81
$5.879
52-Week Range:
$1.68
$10.48
Protara Therapeutics Inc Stock (TARA) Company Profile
Name
Protara Therapeutics Inc
Sector
Industry
Phone
646-844-0337
Address
345 PARK AVENUE SOUTH, NEW YORK, NY
Compare TARA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TARA
Protara Therapeutics Inc
|
5.34 | 201.40M | 0 | -42.05M | -35.26M | -2.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.62 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
472.68 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
552.20 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
809.14 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
331.45 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Protara Therapeutics Inc Stock (TARA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-16-25 | Initiated | Scotiabank | Sector Outperform |
| Mar-14-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-10-23 | Resumed | Guggenheim | Buy |
| Jun-04-21 | Initiated | H.C. Wainwright | Buy |
| Feb-17-21 | Initiated | Oppenheimer | Outperform |
| Oct-19-20 | Initiated | Cowen | Outperform |
| Jul-29-20 | Initiated | Guggenheim | Buy |
View All
Protara Therapeutics Inc Stock (TARA) Latest News
How institutional ownership impacts Protara Therapeutics Inc. stock2025 Institutional Moves & Weekly Setup with High ROI Potential - newser.com
Trend analysis for Protara Therapeutics Inc. this weekSell Signal & AI Based Trade Execution Alerts - newser.com
How to forecast Protara Therapeutics Inc. trends using time seriesJuly 2025 Patterns & Stock Market Timing Techniques - newser.com
Exit strategy if you’re trapped in Protara Therapeutics Inc.Bond Market & Capital Efficiency Focused Ideas - newser.com
Will Protara Therapeutics Inc. bounce back from current supportJuly 2025 Patterns & Precise Swing Trade Entry Alerts - newser.com
Can a trend reversal in Protara Therapeutics Inc. lead to recoveryMarket Activity Summary & Real-Time Sentiment Analysis - newser.com
What is the fair value estimate for Protara Therapeutics Inc. (1KPA) stock in 2025Quarterly Growth Report & Verified Short-Term Trading Plans - newser.com
How Protara Therapeutics Inc. (1KPA) stock reacts to fiscal policiesEarnings Performance Report & Verified Short-Term Plans - newser.com
Custom watchlist performance reports with Protara Therapeutics Inc.July 2025 Action & Technical Pattern Based Buy Signals - newser.com
Why hedge funds are buying Protara Therapeutics Inc. stockShare Buyback & Verified Momentum Stock Watchlist - newser.com
Protara Therapeutics' (TARA) "Sell (D-)" Rating Reiterated at Weiss Ratings - MarketBeat
Protara Therapeutics, Inc. (NASDAQ:TARA) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Protara Therapeutics, Inc. (NASDAQ:TARA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Key resistance and support levels for Protara Therapeutics Inc.2025 Price Action Summary & Verified Technical Signals - newser.com
Advanced analytics toolkit walkthrough for Protara Therapeutics Inc.2025 Sector Review & Risk Adjusted Buy and Sell Alerts - newser.com
Is Protara Therapeutics Inc. stock a contrarian buyProfit Target & Trade Opportunity Analysis - newser.com
Is Protara Therapeutics Inc. showing signs of accumulationWeekly Profit Analysis & Weekly Chart Analysis and Trade Guides - newser.com
NMIBC Market to Experience Notable Growth in Forecast Span - openPR.com
Will Protara Therapeutics Inc. stock sustain high P E ratiosSwing Trade & Long-Term Safe Investment Ideas - newser.com
Will Protara Therapeutics Inc. (1KPA) stock see valuation expansion2025 Volume Leaders & Low Risk High Win Rate Stock Picks - newser.com
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Biotech Firm Protara Therapeutics Issues $4.41 Stock Options and RSUs in Key Employee Grant - Stock Titan
JonesTrading Maintains Protara Therapeutics(TARA.US) With Buy Rating, Maintains Target Price $21 - 富途牛牛
Is Protara Therapeutics Inc. forming a reversal pattern2025 Trading Volume Trends & Expert Curated Trade Setup Alerts - newser.com
Protara Therapeutics Inc Stock (TARA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Protara Therapeutics Inc Stock (TARA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Zummo Jacqueline | Chf Scientific Operations Off |
Mar 26 '25 |
Sale |
4.53 |
21,224 |
96,145 |
98,861 |
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):